“The increase in collaborative arrangements revenue of $ 30.5 million for the three months ended September 30, 2025 compared to the three months ended September 30, 2024 was primarily related to a $ 30.8 million increase in our share of net profits from the sale of LINZESS in the U.S., which was driven by increased net price and increased prescription demand. The decrease in collaborative arrangements revenue of $ 12.4 million for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024 was primarily related to a $ 7.9 million decrease in our share of net profits from the sale of LINZESS in the U.S, resulting from decreased net price, partially offset by increased prescription demand.”
“The average interest rate on our mortgage borrowings, excluding the impact of interest rate swap periodic income, decreased 69 basis points for the three months ended March 31, 2026, due to a decline in short-term interest rates.”
“Selling, general and administrative expenses decreased by $12.2 million for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 , primarily due to a $6.4 million decrease in compensation, benefits, and other employee-related expenses and a $0.9 million decrease in sales and marketing expenses, both resulting from the restructuring initiatives during 2025, as well as a decrease of $5.3 million in professional services expenses. Restructuring expenses.”